Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

British Journal of Cancer

Volumn 100, Issue 8, 2009, Pages 1267-1276

  Cao, P ^a   Maira, S M ^b   Garcia Echeverria C ^b   Hedley, D W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Drug treatment; MTor; Pancreatic cancer; PI3K; Primary xenograft

Indexed keywords

IMIDAZOQUINOLINE DERIVATIVE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NVP BEZ235; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN S6; PROTEIN TYROSINE KINASE; SERINE; THREONINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PHARMACODYNAMICS; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CHILD; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; PANCREATIC NEOPLASMS; PROTEIN KINASES; QUINOLINES; TRANSPLANTATION, HETEROLOGOUS;

EID: 64949155000     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604995     Document Type: Article

References (29)

1. Agbunag C, Bar-Sagi D (2004) Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 64: 5659-5663
2. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, Schafer H (2003) Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251
3. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA (2004) The PI3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells 4. Oncogene 23: 8571-8580
4. Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A (2008) Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol 75: 1035-1044
5. Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909
6. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ (2002) Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1:989-997
7. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence Jr JC, Abraham RT (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15: 5256-5267
8. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, Bernhard EJ (2005) Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras 2. Cancer Res 65: 8433-8441
9. Capella G, Farre L, Villanueva A, Reyes G, Garcia C, Tarafa G, Lluis F (1999) Orthotopic models of human pancreatic cancer. Ann NY Acad Sci 880: 103-109
10. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM (2006) Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma 1. Ann Surg Oncol 13: 933-939
11. DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW (2003) Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 22: 7781-7795
12. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery 12. Nat Rev Drug Discov 4: 988-1004
13. Korc M (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7: 25-41
14. Mackenzie MJ (2004) Molecular therapy in pancreatic adenocarcinoma 2. Lancet Oncol 5: 541-549
15. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De PA, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863
16. Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ (2008) Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 14: 892-900
17. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group 2. J Clin Oncol 25: 1960-1966
18. Ng SS, Tsao MS, Nicklee T, Hedley DW (2001) Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immuno-deficient mice. Clin Cancer Res 7: 3269-3275
19. Ng SS, Tsao MS, Nicklee T, Hedley DW (2002) Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1: 777-783
20. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M (2006) An in vivo platform for translational drug development in pancreatic cancer 5. Clin Cancer Res 12: 4652-4661
21. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR (1998) Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas 17. Mol Carcinog 21: 81-86
22. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, Garcia-Echeverria C, Maira SM (2008) Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 68: 6598-6607
23. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di CS, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030
24. Stauffer F, Garcia-Echeverria C, Furet P, Schnell C, Ruetz S, Maira M, Fritsch CM (2007) Biochemical, cellular and in vivo profiling of a new PI3K inhibitor from the imidazoquinoline series. Proc Am Assoc Cancer Res abstract
25. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425: 851-856
26. Vogt PK, Bader AG, Kang S (2006) Phosphoinositide 3-kinase: from viral oncoprotein to drug target 3. Virology 344: 131-138
27. Woodgett JR (2005) Recent advances in the protein kinase B signaling pathway 5. Curr Opin Cell Biol 17: 150-157
28. Workman P, Clarke PA, Guillard S, Raynaud FI (2006) Drugging the PI3 kinome 7. Nat Biotechnol 24: 794-796
29. Yau CY, Wheeler JJ, Sutton KL, Hedley DW (2005) Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts 1. Cancer Res 65: 1497-1504